Overview

• Biotechnology firm reported net loss of $201.1 mln for 2025, slightly up from 2024

• Company's cash position decreased to $191 mln as of December 31, 2025

• Plans to file IND and CTA for Wilson Disease and AATD programs in 2026

Outlook

• Prime Medicine plans IND/CTA submissions for Wilson Disease and AATD in 2026

• Company expects initial clinical data for Wilson Disease and AATD programs in 2027

• Prime Medicine anticipates cash runway into 2027

Result Drivers

• HIGHER RESEARCH AND DEVELOPMENT (R&D) EXPENSES: R&D expenses were $160.6 million for the year ended December 31, 2025, as compared to $155.3 million for the year ended December 31, 2024.

• HIGHER GENERAL AND ADMINISTRATIVE (G&A) EXPENSES: G&A expenses were $52.3 million for the year ended December 31, 2025, as compared to $50.2 million for the year ended December 31, 2024.

Company press release: ID:nGNX2dGbRh

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY EPS		-$1.35
FY Net Income		-$201.14 mln
FY Income from Operations		-$208.35 mln
FY Operating Expenses		$212.98 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Prime Medicine Inc is $6.00, about 28.8% above its March 2 closing price of $4.66

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.